Molecular Partners AG (SWX:MOLN)
3.040
-0.050 (-1.62%)
Jun 22, 2026, 5:31 PM CET
Molecular Partners AG Employees
Molecular Partners AG had 134 employees as of December 31, 2025. The number of employees decreased by 25 or -15.46% compared to the previous year.
Employees
134
Change (1Y)
-25
Growth (1Y)
-15.46%
Revenue / Employee
n/a
Profits / Employee
-433.01K CHF
Market Cap
115.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 134 | -25 | -15.46% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bachem Holding AG | 2,595 |
| Idorsia | 487 |
| Basilea Pharmaceutica AG | 189 |
| Santhera Pharmaceuticals Holding AG | 94 |
| BioVersys AG | 33 |
| Newron Pharmaceuticals | 27 |
| Xlife Sciences AG | 20 |
| Addex Therapeutics | 3 |
Molecular Partners AG News
- 23 days ago - Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 - GlobeNewsWire
- 26 days ago - Molecular Partners AG Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 27 days ago - Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit - GlobeNewsWire
- 5 weeks ago - Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 - GlobeNewsWire
- 5 weeks ago - Molecular Partners AG Earnings release: Q1 2026 - Filings
- 5 weeks ago - Molecular Partners AG Slides: Corporate presentation - Filings
- 7 weeks ago - Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences - GlobeNewsWire
- 7 weeks ago - Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling - GlobeNewsWire